Ad-REIC/Dkk-3

Developed for: prostate cancer
Investigated by: Icahn School of Medicine at Mount Sinai · Momotaro-Gene Inc.

today NCT01197209 · Ph 1

20112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01197209	Sep → Dec 2010	prostate cancer	Momotaro-Gene Inc.	Withdrawn	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Ad-REIC/Dkk-3	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01197209 ↗
Route	Other	“three 1 mL injections (3 mL total volume) of Ad-REIC/Dkk-3 into the prostate” NCT01197209 ↗